About

Rose Pharma, Inc. is a clinical-stage biopharmaceutical company developing a differentiated, short-acting GLP-1 designed to fill the critical market gap in weight loss maintenance, improved tolerability, and IBS pain reduction.

We are personally committed to reshaping the treatment landscape for people trying to maintain a healthy weight and people living with acute IBS pain. Founded by a team with a proven track record in GLP-1 innovation and market creation, our mission is to fill critical gaps in care—and to improve the lives of patients who need better options

With a multibillion-dollar market opportunity, our Phase 2b asset, ROSE-010 offers a high-value commercial potential in the rapidly expanding GLP-1 space. We are actively seeking corporate partnerships for development and commercialization of ROSE-010 in IBS pain and weight loss management.

Given by subcutaneous injection or possible inhaled delivery, ROSE-010 is rapid acting and short lasting making it ideally suited to target appetite reduction around mealtimes without the constant side effects experienced by many who take long acting GLP-1’s.

ROSE-010 is also being developed for the treatment of pain associated with IBS for use “as needed” in response to acute pain episodes which effects approximately 6-10% of the population in the world.  In the most severe cases, symptoms significantly impact daily life which drives our mission to create a solution for people living with pain associated to IBS.